I'm definitely in that camp, FDA approval was priced in long ago. That boat left the dock when we received very positive feedback from the FDA last year. What's not priced in are the sales and earnings to come (in my view). I don't think the market is thinking about just how large the addressable market is, nor is it considering all the future products/indications that will further expand that addressable market. That's why I continue to be very bullish on this.
Ann: FDA Approves Sofdra, page-492
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $770.9M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 43.3¢ | 41.5¢ | $2.522M | 5.956M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 438567 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 219437 | 9 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |